Hormonal Contraception Articles & Analysis: Older
15 news found
Available therapeutics for endometriosis are mainly hormone-based and aim to reduce the effect of endogenous estrogen. Therefore, hormonal contraceptives, as well as agents which completely shut off estrogen production, are often used. However, interfering with the normal female hormone levels often lead to side effects and such ...
About Evofem Biosciences Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved ...
(NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). ...
"We believe this is a huge step forward toward ensuring contraceptive access for all women at zero copay under the Affordable Care Act (ACA), further reducing unintended pregnancies in the U.S., and helping women get access to Phexxi, an innovative hormone-free birth control," said Saundra Pelletier, CEO of Evofem Biosciences. ...
Chief Executive Officer Saundra Pelletier will provide an update on the commercialization of Evofem's hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate) as well as the Company's pipeline, including the ongoing Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and the recently ...
OB-002 was 100% effective in blocking transmission of HIV infection in a non-human primate model.1 A 15-subject Phase 1 study of vaginally administered OB-002 gel demonstrated that the OB-002 gel was safe and well tolerated, with no evidence of systemic absorption.2 Phexxi is a hormone-free, on-demand prescription contraceptive vaginal gel that was launched in ...
"We are also diligently reducing our quarterly net cash burn rate and expect it will decrease by at least $10 million from Q3 levels starting in the fourth quarter of 2021." Phexxi is a hormone-free, on-demand prescription contraceptive vaginal gel. Evofem launched its celebrity "House Rules" DTC campaign, featuring actress Annie Murphy, in September 2021 to ...
About Evofem Biosciences Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products and product candidates to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's ...
This trial on ADAM is believed to be the first clinical trial on a non-hormonal male contraceptive device in over 20 years. “The Contraline team has designed a novel hydrogel and insertion procedure that has great potential to achieve the safety, durability, and efficacy required for a world-changing new male contraceptive. Currently, ...
Additionally, in 2020, the foundation awarded a $4.2 million grant to Exscientia to identify new innovative treatments for malaria and tuberculosis – two of the world’s leading infectious disease killers – as well as new medicines for non-hormonal contraception. About Exscientia Exscientia is an AI-driven pharmatech company committed to ...
Contraline's project, "Clinical Translation of a Male Contraceptive Procedure" will involve collaborating with UVA and VCU to prepare the company's lead product ADAM™ for use in humans. ...
Contraline's project, "Clinical Translation of a Male Contraceptive Procedure" will involve collaborating with UVA and VCU to prepare the company's lead product ADAM™ for use in humans. ...
Charlottesville, VA – Male Contraceptive Initiative (MCI), a private non-profit foundation, announced the award of a $200,000 grant to the medical device company Contraline, Inc. for the development of a novel vas-occlusive contraceptive device. ...
Mark Prausnitz at Georgia Tech developed dissolving microneedle patches that administer a long-acting contraceptive for more than 30 days using microneedle technology licensed exclusively to Micron Biomedical. ...
His talk, titled “The Past, Present, and Future of Vas-Occlusive Medical Devices,” will be part of the symposium on male contraception on April 24th. The commercialization potential of methods to occlude the vas deferens have promise to be the first long-lasting, non-hormonal, and reversible male contraceptive approach. ...